Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry by 68% market shares.
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44%. The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.
The global Glucagon Like Peptide-1 (GLP-1) Agonists market was valued at US$ 7781.9 million in 2020 and is expected to reach US$ 18650 million by the end of 2029, growing at a CAGR of 13.3% during 2021-2029.
This report focuses on Glucagon Like Peptide-1 (GLP-1) Agonists volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Glucagon Like Peptide-1 (GLP-1) Agonists market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Glucagon Like Peptide-1 (GLP-1) Agonists Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2029. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Segment by Application
Hospital
Pharmacy
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Amylin
1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Overview
1.1 Product Overview and Scope of Glucagon Like Peptide-1 (GLP-1) Agonists
1.2 Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Type
1.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate Comparison by Type (2021-2029)
1.2.2 Exenatied
1.2.3 Liraglutide
1.2.4 Lixisenatide
1.2.5 Albiglutide
1.2.6 Dulaglutide
1.3 Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Application
1.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Comparison by Application: (2021-2029)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Estimates and Forecasts
1.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue 2016-2029
1.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales 2016-2029
1.4.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region: 2016 Versus 2021 Versus 2029
2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Competition by Manufacturers
2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Manufacturers (2016-2021)
2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Sites, Area Served, Product Type
2.5 Glucagon Like Peptide-1 (GLP-1) Agonists Market Competitive Situation and Trends
2.5.1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Glucagon Like Peptide-1 (GLP-1) Agonists Players Market Share by Revenue
2.5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Glucagon Like Peptide-1 (GLP-1) Agonists Retrospective Market Scenario by Region
3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
3.3.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country
3.3.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
3.4.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country
3.4.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Region
3.5.1 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region
3.5.2 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
3.6.1 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country
3.6.2 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
3.7.1 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country
3.7.2 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Historic Market Analysis by Type
4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2016-2021)
4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2016-2021)
4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2016-2021)
5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Historic Market Analysis by Application
5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2016-2021)
5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2016-2021)
5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Corporation Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
6.2.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Eli Lily
6.3.1 Eli Lily Corporation Information
6.3.2 Eli Lily Description and Business Overview
6.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.3.5 Eli Lily Recent Developments/Updates
6.4 GSK
6.4.1 GSK Corporation Information
6.4.2 GSK Description and Business Overview
6.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
6.4.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.4.5 GSK Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Corporation Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.6.5 Bristol-Myers Squibb Recent Developments/Updates
6.7 Amylin
6.6.1 Amylin Corporation Information
6.6.2 Amylin Description and Business Overview
6.6.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.7.5 Amylin Recent Developments/Updates
7 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Cost Analysis
7.1 Glucagon Like Peptide-1 (GLP-1) Agonists Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Glucagon Like Peptide-1 (GLP-1) Agonists
7.4 Glucagon Like Peptide-1 (GLP-1) Agonists Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List
8.3 Glucagon Like Peptide-1 (GLP-1) Agonists Customers
9 Glucagon Like Peptide-1 (GLP-1) Agonists Market Dynamics
9.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
9.2 Glucagon Like Peptide-1 (GLP-1) Agonists Growth Drivers
9.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges
9.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints
10 Global Market Forecast
10.1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Glucagon Like Peptide-1 (GLP-1) Agonists by Type (2022-2029)
10.1.2 Global Forecasted Revenue of Glucagon Like Peptide-1 (GLP-1) Agonists by Type (2022-2029)
10.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Glucagon Like Peptide-1 (GLP-1) Agonists by Application (2022-2029)
10.2.2 Global Forecasted Revenue of Glucagon Like Peptide-1 (GLP-1) Agonists by Application (2022-2029)
10.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Glucagon Like Peptide-1 (GLP-1) Agonists by Region (2022-2029)
10.3.2 Global Forecasted Revenue of Glucagon Like Peptide-1 (GLP-1) Agonists by Region (2022-2029)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) Growth Rate Comparison by Type (2021-2029)
Table 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) Comparison by Application (2021-2029)
Table 3. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region (US$ Million) (2016 VS 2021 VS 2029)
Table 4. Key Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Covered in This Study
Table 5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Glucagon Like Peptide-1 (GLP-1) Agonists Average Price (USD/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Sites and Area Served
Table 11. Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Glucagon Like Peptide-1 (GLP-1) Agonists as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2016-2021) & (K Units)
Table 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2016-2021)
Table 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021) & (K Units)
Table 19. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2016-2021)
Table 20. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2016-2021)
Table 22. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021) & (K Units)
Table 23. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2016-2021)
Table 24. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2016-2021)
Table 30. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021) & (K Units)
Table 31. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2016-2021)
Table 32. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2016-2021)
Table 38. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) by Type (2016-2021)
Table 39. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2016-2021)
Table 40. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Million US$) by Type (2016-2021)
Table 41. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2016-2021)
Table 42. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit) by Type (2016-2021)
Table 43. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) by Application (2016-2021)
Table 44. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2016-2021)
Table 45. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Million US$) by Application (2016-2021)
Table 46. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2016-2021)
Table 47. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit) by Application (2016-2021)
Table 48. Novo Nordisk Corporation Information
Table 49. Novo Nordisk Description and Business Overview
Table 50. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 51. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 52. Novo Nordisk Recent Developments/Updates
Table 53. AstraZeneca Corporation Information
Table 54. AstraZeneca Description and Business Overview
Table 55. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 56. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 57. AstraZeneca Recent Developments/Updates
Table 58. Eli Lily Corporation Information
Table 59. Eli Lily Description and Business Overview
Table 60. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 61. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 62. Eli Lily Recent Developments/Updates
Table 63. GSK Corporation Information
Table 64. GSK Description and Business Overview
Table 65. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 66. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 67. GSK Recent Developments/Updates
Table 68. Sanofi Corporation Information
Table 69. Sanofi Description and Business Overview
Table 70. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 71. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 72. Sanofi Recent Developments/Updates
Table 73. Bristol-Myers Squibb Corporation Information
Table 74. Bristol-Myers Squibb Description and Business Overview
Table 75. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 76. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 77. Bristol-Myers Squibb Recent Developments/Updates
Table 78. Amylin Corporation Information
Table 79. Amylin Description and Business Overview
Table 80. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 81. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 82. Amylin Recent Developments/Updates
Table 83. Production Base and Market Concentration Rate of Raw Material
Table 84. Key Suppliers of Raw Materials
Table 85. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List
Table 86. Glucagon Like Peptide-1 (GLP-1) Agonists Customers List
Table 87. Glucagon Like Peptide-1 (GLP-1) Agonists Market Trends
Table 88. Glucagon Like Peptide-1 (GLP-1) Agonists Growth Drivers
Table 89. Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges
Table 90. Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints
Table 91. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Type (2022-2029) & (K Units)
Table 92. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Type (2022-2029)
Table 93. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Type (2022-2029) & (US$ Million)
Table 94. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share Forecast by Type (2022-2029)
Table 95. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Application (2022-2029) & (K Units)
Table 96. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Application (2022-2029)
Table 97. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Application (2022-2029) & (US$ Million)
Table 98. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share Forecast by Application (2022-2029)
Table 99. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Region (2022-2029) & (K Units)
Table 100. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Region (2022-2029)
Table 101. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Region (2022-2029) & (US$ Million)
Table 102. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share Forecast by Region (2022-2029)
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Glucagon Like Peptide-1 (GLP-1) Agonists
Figure 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Type in 2020 & 2029
Figure 3. Exenatied Product Picture
Figure 4. Liraglutide Product Picture
Figure 5. Lixisenatide Product Picture
Figure 6. Albiglutide Product Picture
Figure 7. Dulaglutide Product Picture
Figure 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Application in 2020 & 2029
Figure 9. Hospital
Figure 10. Pharmacy
Figure 11. Other
Figure 12. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue, (US$ Million), 2016 VS 2021 VS 2029
Figure 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size 2016-2029 (US$ Million)
Figure 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales 2016-2029 (K Units)
Figure 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Market Share by Region: 2016 VS 20210 VS 2029
Figure 16. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Manufacturers in 2020
Figure 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Manufacturers in 2020
Figure 18. The Global 5 and 10 Largest Glucagon Like Peptide-1 (GLP-1) Agonists Players: Market Share by Revenue in 2020
Figure 19. Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 20. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2016-2021)
Figure 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region in 2020
Figure 22. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2016-2021)
Figure 23. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region in 2020
Figure 24. U.S. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. France Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Russia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. India Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Australia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Taiwan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Indonesia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Thailand Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Malaysia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Philippines Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Vietnam Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. U.A.E Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. Sales Market Share of Glucagon Like Peptide-1 (GLP-1) Agonists by Type (2016-2021)
Figure 49. Sales Market Share of Glucagon Like Peptide-1 (GLP-1) Agonists by Application (2016-2021)
Figure 50. Sales Market Share of Glucagon Like Peptide-1 (GLP-1) Agonists by Application in 2020
Figure 51. Revenue Share of Glucagon Like Peptide-1 (GLP-1) Agonists by Application (2016-2021)
Figure 52. Revenue Share of Glucagon Like Peptide-1 (GLP-1) Agonists by Application in 2020
Figure 53. Manufacturing Cost Structure of Glucagon Like Peptide-1 (GLP-1) Agonists
Figure 54. Manufacturing Process Analysis of Glucagon Like Peptide-1 (GLP-1) Agonists
Figure 55. Glucagon Like Peptide-1 (GLP-1) Agonists Industrial Chain Analysis
Figure 56. Channels of Distribution
Figure 57. Distributors Profiles
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
The research methodology employed by VICResearch has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of VICResearch. VICResearch’s methodology can be divided into five stages:
Stage 1: Secondary research
The research team first works with magazines, industry trade group, and administration that operate in the research field. The information provided by our in-house documentation service helps us carrying out further research. Our team which has the experience as well as the knowledge efficiently extracts the accurate information from existing source.
Stage 2: Primary research: interviews with trade sources
After the first stage, the research team conducts large number of face-to-face or telephone interviews with the representative companies operating in the research field. The analysts attempt to obtain a chance to talk with leading players in the field as well as with small companies. The upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers are all included in the interviews. The data gathered during the interview is then carefully checked and compared with the secondary research.
Stage 3: Analysis of the gathered data
The analysis team checks and synthesizes the data gathered during the first two stages. To validate the data, a second series of interviews can be conducted.
Stage 4: Quantitative data
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by VICResearch. The data is based on the estimates obtained during stage 3.
The research team also provides appreciation and analysis of the market and the quantitative data contained in the reports. The data is consequently unique to VICResearch.
Stage 5: Quality control
Before publishing, every report goes under a rigorous checking and editing process, which is done by experience management team to ensure the reliability of the published data. Each analyst in the research team receives support and on-going training which is part of the VICResearch’s internal quality process.
Consulting report: +86-15323335301 020-31521856
